Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.

Clinical Trials Cancer

Newron Needs To Up Ante In Large-Scale Schizophrenia Studies

Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.

Clinical Trials Neurology

Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.

Rare Diseases Research and Development Strategies

Microbiome Market Value To Reach $500m by 2022

The microbiome market will see its value rise to $500m by 2022, and higher during the next decade. The key driver will be the increase in biotech and pharma firms looking at the emerging research space for new therapeutic options to treat chronic conditions such as Crohn’s disease.

Research & Development Research and Development Strategies

NICE Appraisal Changes: Confusing, Contradictory & Questionable

New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.

Pricing Strategies United Kingdom

NICE Appraisal Changes: A New Pricing Hurdle For Companies

New NICE and NHS England appraisal rules regarding timelines and price thresholds – labeled stark and contradictory – could fast-track new cost-effective drugs but then subject the same products to significant delays of multiple years.

Pricing Strategies United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register